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Abstract
Background: A possible synergic role of serum uric acid (SUA) with thrombolytic therapies is controversial and
needs further investigations. We therefore evaluated association of admission SUA with clinical improvement and
clinical outcome in patients receiving rt-PA, early admitted patients not receiving rt-PA, and patients admitted after
time window for rt-PA.
Methods: SUA levels were obtained at admission and categorized as low, middle and high, based on 33° and 66°
percentile values. Patients were categorized as patients admitted within 3 hours of symptom onset receiving rt-PA
(rt-PA group), patients admitted within 3 hours of symptom onset not receiving rt-PA (non-rt-PA group), and
patients admitted after time window for rt-PA (late group). Short-term clinical improvement was defined as the
difference between NIHSS on admission minus NIHSS day 7. Favorable outcome was defined as mRS 0 - 3 and
unfavorable outcome as mRS 4 - 6.
Results: SUA measurements were available in 1136 patients. Clinical improvement was significantly higher in
patients with high SUA levels at admission. After adjustment for possible confounders, SUA level showed a positive
correlation with clinical improvement (r = 0.012, 95% CI 0.002-0.022, p = 0.02) and was an independent predictor
for favorable stroke outcome (OR 1.004; 95% CI 1.0002-1.009; p = 0.04) only in the rt-PA group.
Conclusions: SUA may not be neuroprotective alone, but may provide a beneficial effect in patients receiving
thrombolysis.
Background
Serum uric acid (SUA) is a final enzymatic product of
purine metabolism [1,2]. Animal models of acute
ischemic stroke (AIS) have shown that SUA may be
neuroprotective [3] and may reinforce the benefits of
intravenous thrombolysis (rt-PA) [4]. In humans, high
SUA may be an independent predictor of better out-
come after AIS [5] and represent a consumptive and
reproducible antioxidant in AIS [6,7]. Combined intrave-
nous administration of rt-PA and SUA is safe, prevents
an early decline in SUA levels and decreases lipid perox-
idation but has not shown any clinical effect [8]. On the
other hand, high SUA levels have been also associated
with hypertension [9], dyslipidemia, type 2 diabetes [10],
kidney disease, cardiovascular and cerebrovascular
events [11] and worse functional outcome after AIS
[12]. The role of SUA in AIS is therefore still
controversial, and a possible synergic role of SUA with
thrombolytic therapies needs further investigations.
In the present study we therefore aimed to evaluate
the association of admission SUA levels with short-term
clinical improvement and short-term clinical outcome in
patients receiving rt-PA, patients admitted within 3
hours of symptom onset not receiving rt-PA, and
patients admitted after the time window for rt-PA.
Methods
This prospective study was conducted at Haukeland
University Hospital, Bergen, Norway, which serves a
well-defined population of 235,000 inhabitants. The
study was performed from February 2006 to January
2009 as a part of a cohort study (Bergen NORSTROKE
Study) in which data are collected from all consecutive
ischemic stroke patients admitted to the stroke unit in
the Department of Neurology. All patients were mana-
ged according to a standard protocol and received stan-
dard care as recommended by the European Stroke
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Organisation [13]. Eligible patients received intravenous
rt-PA according to the SITS-MOST protocol [14]. SUA
levels, NIH stroke scale (NIHSS) score, serum creatinine
levels, systolic and diastolic blood pressure were
obtained at admission. Patients with unavailable SUA
levels at admission were excluded from the study.
Patients were categorized as patients admitted within 3
hours of symptom onset receiving rt-PA (rt-PA group),
patients admitted within 3 hours of symptom onset not
receiving rt-PA (non-rt-PA group), and patients
admitted after time window for rt-PA (late group).
Patients were categorized as young (≤ 65 years) and old
(> 65 years). NIHSS scores were categorized as mild (<
8), moderate (8 - 14) and severe (> 14) [15]. Short-term
clinical progress was defined as the difference between
NIHSS on admission (NIHSS0) minus NIHSS at day 7
(NIHSS7) (Δ-NIHSS = NIHSS0 - NIHSS7) [16,17]. A
positive Δ-NIHSS value indicated a clinical improve-
ment whereas a negative value indicated a clinical
worsening.
SUA were categorized as low, middle and high, based
on 33° and 66° percentile values.
The etiology of stroke was classified as large-artery
atherosclerosis, cardioembolism, small vessel occlusion,
stroke of other determined etiology and stroke of unde-
termined etiology based on TOAST criteria [18].
Diabetes mellitus (DM) was defined as treatment with
glucose lowering medications or diet before stroke
onset. Hypertension (HT) was defined as treatment with
antihypertensive drugs before stroke onset. Serum crea-
tinine levels were measured at admission and categor-
ized as normal < 120 μmol/L or high ≥ 120 μmol/L.
Previous stroke or TIA were registered. Seven days after
stroke onset, functional outcome was assessed by modi-
fied Rankin scale (mRS) [19]. Assessment was done by a
trained stroke nurse. Favorable outcome was defined as
mRS 0 - 3 and unfavorable outcome as mRS 4 - 6 [20].
The study was approved by the local research ethics
committee and informed consent was obtained from all
patients as part of a prospective study protocol.
Statistics
Chi-square test, Student’s t-test, and analysis of variance
(ANOVA) were used as appropriate. Age, sex, systolic
blood pressure at admission, serum creatinine, pre-exist-
ing diabetes were considered as possible confounding
factors of SUA level. Multiple linear regression was used
to estimate the relationship between SUA and Δ-NIHSS.
Table 1 Basic Characteristics of the Study Population (n = 1136)
rt-PA Non rt-PA Late p
Sample size, n 186 261 689
Time to blood sample, h (IR) 1.5 (1.0-2.4) 1.9 (1.4-2.7) 18.7 (9.3-31.1)
Age, years (SD) 69.3 (± 14.2) 70.9 (± 14.1) 71.4 (± 14.6) 0.21
Male Sex, n (%) 118 (63.4) 149 (57.1) 385 (± 55.9) 0.17
Median NIHSS day 0* (IR) 9.5 (4-17) 3 (1-5) 3 (1-7) 0.0001
NIHSS day 0, n (%) 0.0001
< 8 76 (40.9) 216 (82.7) 524 (76.1)
8-14 42 (22.6) 13 (7.3) 78 (11.3)
> 14 68 (36.5) 26 (10.0) 87 (12.6)
SUA levels, μmol/L, n (%) 0.2
< 305 56 (29.5) 93 (34.7) 257 (33.5)
305-399 63 (33.2) 100 (37.3) 249 (32.5)
≥ 400 71 (37.4) 75 (28.0) 260 (34.0)
Creatinine, μmol/L, n (%) 0.4
< 120 169 (91.0) 247 (92.1) 687 (89.7)
≥ 120 17 (9.0) 21 (7.9) 79 (10.3)
SBP day 0, mmHg (SD) 162.0 (± 25.9) 168.5 (± 29.3) 167.5 (± 33.6) 0.05
Previous diseases, n (%)
Hypertension 92 (49.5) 133 (50.0) 415 (54.6) 0.3
Diabetes 23 (12.4) 33 (12.6) 119 (15.8) 0.3
Stroke 21 (11.0) 58 (21.7) 145 (19.1) 0.01
TIA 18 (9.4) 28 (10.5) 71 (9.3) 0.8
Median mRS day 7 (IR) 2 (1-4) 2 (1-3) 2 (1-4) 0.01
IR, Interquantile Range; SD, Standard Deviation; NIHSS, National Institutes of Health Stroke Scale; SUA, serum Uric Acid; SBP, systolic blood pressure; TIA, transient
ischemic attack; mRS, modified Rankin Scale
*Day 0: day of admission
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Age, sex, systolic blood pressure at admission, serum
creatinine, pre-existing diabetes and admission NIHSS
score were included as other exposure variables. Logistic
regression analysis was performed to determine factors
that could be considered independent predictors for
stroke outcome. Significance was set at p < 0.05. The
analysis was performed with the software ‘STATA/SE
11.0 for Windows’.
Results
During the study period, 1224 patients with ischemic
stroke were admitted to our department. SUA measure-
ments were available in 1136 patients. Missing values
were due to technical error and may be called protocol
violations. Basic characteristics of the study population
are shown in Table 1. SUA levels related to demo-
graphics and risk factors of the population groups are
shown in Table 2.
Among the three groups, the rt-PA group had the lar-
gest short-term clinical improvement (Table 1). Within
this group, the improvement was significantly larger in
patients with high SUA levels at admission (Table 3).
Multiple linear regression that included patients charac-
teristics (age, gender), stroke characteristics (NIHSS
score at admission) and possible confounding factors for
SUA levels (serum creatinine, systolic blood pressure at
admission) as other exposure variables, showed a posi-
tive correlation between admission SUA levels and
Δ-NIHSS only in the rt-PA group (r = 0.012, 95% CI
0.002-0.022, p = 0.02), Figure 1.
Stepwise logistic regression analysis including the
same covariates as the multiple linear regression, identi-
fied SUA levels as predictor for favorable stroke out-
come (mRS 0-3) only in the rt-PA group (OR 1.004;
95% CI 1.0002-1.009; p = 0.04). Young age and low
NIHSS score at admission were predictors for better
stroke outcome in all the three groups.
Discussion
To be effective, neuroprotective agents should act in the
acute phase of ischemic stroke, before neuronal death
has occurred. We therefore focused our study on SUA
levels measured within the first 3 hours after stroke
onset. Antioxidant agents have so far shown to be effec-
tive only in animal models of AIS, but not in humans
[21]. Potential factors hindering translation of animal
models success into clinical practice may be patient het-
erogeneity, inappropriate dose, and wide time window
Table 2 Serum Uric Acid Levels on admission in Relation to Demographics and Risk Factors in the population
subgroups
SUA at admission, μmol/L (± SD)
rt-PA Non rt-PA Late
n = 186 n = 261 n = 689 p
Overall 361 (± 97) 348 (± 93) 345 (± 104) 0.03
Age
(> 65) 367 (± 101) 358 (± 90) 357 (± 113) 0.6
(≤ 65) 352 (± 92) 330 (± 95) 324 (± 82) 0.01
p* 0.1 0.01 0.0001
Female 331 (± 102) 310 (± 89) 325 (± 111) 0.3
Male 378 (± 90) 377 (± 85) 361 (± 55.9) 0.17
p* 0.0007 0.0001 0.0001
NIHSS day 0
< 8 349 (± 86) 347 (± 91) 341 (± 96) 0.6
8-14 359 (± 107) 351 (± 108) 356 (± 109) 0.9
> 14 375 (± 103) 355 (± 93) 362 (± 137) 0.7
p* 0.2 0.9 0.1
Hypertension
Yes 396 (± 92) 364 (± 94) 365 (± 105) 0.003
No 327 (± 90) 334 (± 88) 321 (± 96) 0.3
p* 0.0001 0.005 0.0001
Diabetes
Yes 372 (± 109) 361 (± 88) 361 (± 113) 0.3
No 360 (± 96) 347 (± 93) 341 (± 101) 0.03
p* 0.3 0.2 0.03
SUA, serum Uric Acid; SD, Standard Deviation; NIHSS, National Institutes of Health Stroke Scale.
* p values for statistical tests assessing difference in SUA between categories of each population subgroup.
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[22]. SUA is a natural antioxidant present in biological
fluids throughout the body, and appears to be the major
endogenous antioxidant [23,24]. However, it has been
controversial whether SUA is neuroprotective or neuro-
toxic. Recently, it has been proposed that SUA may
show both anti- and pro-oxidant properties depending
on levels of other antioxidants, levels of oxidative stress
and time of interaction with the target tissues [25], and
that the balance between the anti- and pro-oxidant
properties shifts in favour of neuroprotection in
conditions of extraordinary oxidative stress such as AIS
[24]. In our study, SUA level did not show any correla-
tion with clinical improvement nor association with bet-
ter clinical outcome in early patients not receiving rt-
PA. Early studies investigating a possible association
between SUA and clinical outcome showed controversial
results [5,12]. However, a potential limitation of these
studies may be the wide time window for SUA measure-
ments (e.g up to 48 and 72 hours). Moreover, the study
which showed that SUA level predicts poor outcome
Figure 1 Correlation between SUA levels and Δ-NIHSS. Age, gender, NIHSS0, serum creatinine and admission systolic blood pressure are
included as other exposure variables in the multiple linear regression model. Δ-NIHSS: NIHSS on admission (NIHSS0) minus NIHSS at day 7
(NIHSS7) rt-PA: r = 0.012, 95% CI 0.002-0.022, p = 0.02 Early, no rt-PA: r = 0.012, 95% CI -0.004-0.007, p = 0.7 Late: r = -0.003, 95% CI -0.006-0.0002,
p = 0.07.
Table 3 Early Clinical Progress (*Δ-NIHSS) and SUA levels (μmol/L) in the three population subgroups
Δ-NIHSS (± SD)
SUA levels All < 305 305-399 ≥ 400 p
rt-PA group 3.62 (± 6.3) 3.0 (± 6.2) 2.2 (± 6.6) 5.2 (± 5.9) < 0.01
Early, no rt-PA 1.2 (± 4.0) 1.4 (± 3.8) 0.8 (± 4.2) 1.3 (± 4.6) 0.2
Late group 1.0 (± 3.7) 1.3 (± 3.1) 0.9 (± 5.2) 1.0 (± 4.4) 0.3
*Δ-NIHSS: NIHSS on admission (NIHSS0) minus NIHSS at day 7 (NIHSS7)
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after AIS [12] included also patients with TIA and intra-
cranial hemorrhage, and did not specify whether a per-
centage of AIS patients received thrombolytic therapy.
Thrombolysis may lead to recanalization which can
salvage viable tissue in the penumbral zone, and is cur-
rently the only approved treatment for acute stroke.
Dual therapy with rt-PA and neuroprotective agents has
shown promising results only in model of AIS [26,27].
Combined administration of uric acid and rt-PA to
adult rats twenty minutes after the induction of ische-
mia caused a significant reduction in infarct volume and
a significant lower neurological impairment [3,4]. In
humans, higher SUA levels in AIS patients receiving rt-
PA have been associated with better outcome at day 90
and smaller infarct volume [28]. In agreement with this,
our study shows that high SUA is independently asso-
ciated with higher short-term clinical improvement and
better short-term clinical outcome in rt-PA patients.
During the first hours of AIS, reactive oxygen species
(ROS) produced by mitochondria play a central patho-
genetic role in neuronal death. A further burst of ROS
occurs during the early tissue reperfusion induced by
recanalization [29]. Serial SUA measurements have
shown that SUA is consumed during the first six hours
after stroke [6,7], suggesting that SUA represents a con-
sumptive and reproducible antioxidant in AIS. SUA may
therefore supply an additional beneficial effect to rt-PA
by acting as a scavenger engulfing ROS released during
the early recanalization induced by rt-PA. Even though
we do not have data on recanalization rate, this is likely
to be higher in the rt-PA group than in the early non-
rt-PA group.
Conclusion
In our study high SUA was independently associated
with higher short-term clinical improvement and better
short-term clinical outcome in rt-PA patients whereas
no association was found in early patients not receiving
rt-PA or in late patients. SUA may not achieve clinical
effect alone, but may provide an additional beneficial
effect in patients receiving recanalizing therapies.
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